Scholarlink

<p>Imatinib &amp; Dasatinib Are Two Most Commonly Used Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Dasatinib at Approved Dose of 100 Mg Causes Myelosuppression &amp; pleuro-pulmonary Toxicity Leading To Drug Discontinuation &amp; Treatment Failure, so 50 Mg Is an Option. Therefore, this Study Was Undertaken To Determine the Cytogenetic &amp; Molecular Response with Dasatinib 50 Mg &amp; To Assess its Adverse Effects. It is a prospective study from July 2021 to December 2022 with a sample size of 58. Newly diagnosed patients of CML CP, after considering the inclusion &amp; exclusion criteria, were evaluated at baseline. They were started on 50&#xa0;mg of Dasatinib &amp; followed up weekly for first 4weeks, then monthly for two months, at 3 month &amp; at 6 month with CBC &amp; monitoring of toxicities. Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR: :ABL1 transcript from peripheral blood was performed at 3 &amp; 6 month.&#xa0;Median age of the study population was 37(thirty-seven). 61% &amp; 65% patients attained optimum molecular milestone at 3 month &amp; 6 month respectively. 27% patients achieved major molecular response (MMR) (BCR::ABL &lt; 0.1%) at 6 month. we found a statistically significant correlation between baseline total leucocyte count (TLC) &amp; achievement of BCR::ABL &lt; 10% at 3 month. Total 26(45%) adverse events noted, most common being neutropenia. Median duration of dose interruption was 29 days with a range of 10–70 days.&#xa0;27% attained MMR at 6 month. One (1) patient developed grade 3 pleural effusion &amp; succumbed to complication. 20% patients failed to achieve optimum molecular response at 6 month with most common adverse effect being neutropenia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Study on Efficacy and Safety of Dasatinib 50 Mg in Newly Diagnosed Patients of Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Experience From a Tertiary Care Hospital

  • 期刊论文

  • 发表日期：

    2025年9月3日

查看全文
  • Apurba Banerjee,
  • Shuvra Neel Baul,
  • Sandeep Saha,
  • Abhishek Sharma,
  • Rajib De,
  • Tuphan Kanti Dolai

摘要

Imatinib & Dasatinib Are Two Most Commonly Used Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Dasatinib at Approved Dose of 100 Mg Causes Myelosuppression & pleuro-pulmonary Toxicity Leading To Drug Discontinuation & Treatment Failure, so 50 Mg Is an Option. Therefore, this Study Was Undertaken To Determine the Cytogenetic & Molecular Response with Dasatinib 50 Mg & To Assess its Adverse Effects. It is a prospective study from July 2021 to December 2022 with a sample size of 58. Newly diagnosed patients of CML CP, after considering the inclusion & exclusion criteria, were evaluated at baseline. They were started on 50 mg of Dasatinib & followed up weekly for first 4weeks, then monthly for two months, at 3 month & at 6 month with CBC & monitoring of toxicities. Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR: :ABL1 transcript from peripheral blood was performed at 3 & 6 month. Median age of the study population was 37(thirty-seven). 61% & 65% patients attained optimum molecular milestone at 3 month & 6 month respectively. 27% patients achieved major molecular response (MMR) (BCR::ABL < 0.1%) at 6 month. we found a statistically significant correlation between baseline total leucocyte count (TLC) & achievement of BCR::ABL < 10% at 3 month. Total 26(45%) adverse events noted, most common being neutropenia. Median duration of dose interruption was 29 days with a range of 10–70 days. 27% attained MMR at 6 month. One (1) patient developed grade 3 pleural effusion & succumbed to complication. 20% patients failed to achieve optimum molecular response at 6 month with most common adverse effect being neutropenia.